Available Technologies

ADDITIONAL FILTERS

294 available technologies

Simultaneous RNA and Gene Expression Profiling Using Mass Spectrometry

This technology allows the simultaneous detection of RNA transcript abundance (as an assay of gene expression) and protein abundance (as an assay of protein expression) from biological samples without RNA isolation, labeling or amplification. Existing technologies allow for very efficient determinations of protein abundance from a wide variety of biological samples. These methods are in widespread use and are based on mass spectrometry technologies. There are no available technologies that allow efficient and quantitative assessment of multiple RNA transcripts without a previous isolation followed by labeling and/or amplification. The most efficient technologies currently available make use of DNA microarrays to profile RNA abundance as a measure of gene expression. While very robust and useful, these technologies are very labor intensive and suffer from a number of technological drawbacks. This technology takes advantage of a number of existing methods and techniques and brings them together in a novel manner that greatly expands the state of the art for gene expression.

KnowledgeMap: Comprehensive Curriculum Content Management and Mapping System for Medical Education

KnowledgeMap is a web accessible comprehensive content management system with robust mapping capabilities across the entire curriculum (at the level of full lectures, not just outlines or syllabi) that facilitates overall design, management, and evaluation of a coherent and coordinated curriculum.

New Drug for Blood Clot: FXII Inhibitors to Treat Thrombosis

Thrombosis is the formation of a blood clot inside a blood vessel, which may cause reduced blood flow to a tissue, or even tissue death. Thrombosis, inflammation, and infections are responsible for >70% of all human mortality. Thrombosis is also the major factor for heart disease and stroke. 500,000 die from thrombosis every year in Europe. Inhibitory treatment of these conditions may also improve the outcomes of several non-fatal diseases. Researchers from Vanderbilt University and Oregon Health & Science University have jointly discovered new monoclonal antibodies that potently inhibit the blood coagulation protein factor XII (FXII), a critical player in the pathway, and anticoagulate blood. This invention provides foundation for commercial development of anti-thrombotic drugs based on new molecular entities.

Method of Preparing Vanadium Dioxide Nanoparticles

This technology provides a method for preparing VO2 nanoparticles having controlled size utilizing inverse micelle hydrolysis

OLINDA/EXM Radiation Dose Assessment Software Application (FDA Approved)

The OLINDA/EXM® personal computer code performs dose calculations and kinetic modeling for radiopharmaceuticals (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling). OLINDA® calculates radiation doses to different organs of the body from systemically administered radiopharmaceuticals and performs regression analysis on user-supplied biokinetic data to support such calculations for nuclear medicine drugs. These calculations are used to perform risk/benefit evaluations of the use of such pharmaceuticals in diagnostic and therapeutic applications in nuclear medicine. The technology employs a number of standard body models for adults, children, pregnant women and others, that are widely accepted and used in the internal dose community. The calculations are useful to pharmaceutical industry developers, nuclear medicine professionals, educators, regulators, researchers and others who study the accepted radiation doses that should be delivered when radioactive drugs are given to patients or research subjects.

Catheter Having Temperature Controlled Anchor and Related Methods

Heart valve disease is the 3rd most prevalent source of cardiovascular disease, leading to approximately 20,000 deaths per year in the U.S. alone. Moreover, there are an estimated 41,000 mitral valve procedures performed in the U.S. each year. The only effective, long-term treatment for mitral valve disease is open-chest valve replacement surgery, which is highly undesirable for elderly patients. Thus, there is a pressing need to develop novel percutaneous strategies for treatment that will reduce the number of open-chest surgeries. David Merryman and colleagues have developed a new, combined catheter that uses cryo temperatures to adhere to moving mitral valve leaflets and radiofrequency ablation to alter the compliance of the leaflet tissue to prevent prolapse and regurgitation.

Gene and Mutations Causative for Familial Primary Pulmonary Hypertension

This invention relates generally to a method of identifying an individual having an increased susceptibility to developing Familial Primary Pulmonary Hypertension (FPPH), as well as to a method for diagnosing an individual suffering from FPPH. The invention also relates to a method of identifying an individual having an increased susceptibility to developing (non-familial) Primary Pulmonary Hypertension (PPH), as well as to a method for diagnosing an individual suffering from PPH.

Olfactory Genes from the Malaria Mosquito

This technology facilitates the discovery and design of novel agents for either repelling or otherwise controlling insects that have important economic or medical significance. In particular, mosquitoes are responsible for transmitting a number of diseases, including malaria, West Nile, dengue and yellow fevers. The Zwiebel laboratory has identified human odorants and the protein receptors in mosquitoes that allow female mosquitoes to identify their hosts when they need blood to satisfy their reproductive needs. With funding from the Gates Foundation's Grand Challenge in Global Health initiative, the Zwiebel laboratory, along with collaborators at Yale, Wageningen University in the Netherlands, and researchers in Africa, developed biological and behavioral assays to screen and test numerous agents as potential repellants and attractants for the Anopholes gambiae mosquito.
These methods have been applied to include agricultural pests, disease vectors and nuisance insects (important for many tourist-based economies).

Method to Detect PDE Inhibitor Binding

Phosphodiesterase-5 (PDE5) is an enzyme which degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. The common known drug Viagra is similar in molecular structure to cGMP and acts as a competitive binding agent of PDE5. Thus in the presence of Viagra unbound cGMP levels increase which results in smooth muscle relaxation or vasodilation leading to an increased inflow of blood. Vanderbilt researchers have developed a method for assaying compounds which bind PDEs. Not only will this method be useful in identify other PDE inhibitors but due to the high affinity of this system this method could be used to identify and isolate PDEs from various crude tissue fractions.

Lipoxygenase Proteins and Nucleic Acids

Isolated and purified lipoxygenase proteins and nucleic acids are described. Particularly, a novel human 15(S) lipoxygenase (15-Lox-2) protein and cDNA and a cDNA for mouse 8S-lipoxygenase are described. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also described, along with methods of producing each. Isolated and purified antibodies to 15-Lox-2 and 8-Lox, and methods of producing the same, are also described.

Guava (Psidium Guajava) 13-Hydroperoxide Lyase and Uses Thereof

This invention relates to fatty acid 13-hydroperoxide lyase protein from guava (Psidium guajava) and the gene encoding the protein. Expression systems for recombinant guava 13-hydroperoxide lyase and methods of using recombinant guava 13-hydroperoxide lyase for the production of green notes are provided.

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter